Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
This accelerated maturation means the wound progresses through healing phases more quickly, potentially reducing the window of vulnerability where complications can develop
Our Process Step 1 Virtual Consult Complete a comprehensive health assessment with one of our licensed medical providers
While compounds like TB-500 are excellent for muscle and large tissue injuries, they lack the specific neuro-protective mechanism of ARA-290
The structure is similar to GHK-Cu but with alanine replacing glycine as the first amino acid
